Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Survival time following resection of intracranial metastases from NSCLC-development and validation of a novel nomogram

Authors: Xiaoyu Ji, Yingjie Zhuang, Xiangye Yin, Qiong Zhan, Xinli Zhou, Xiaohua Liang

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Brain metastases (BM) from non-small cell lung cancer (NSCLC) are the most frequent intracranial tumors. To identify patients who might benefit from intracranial surgery, we compared the six existing prognostic indexes(PIs) and built a nomogram to predict the survival for NSCLC with BM before they intended to receive total intracranial resection in China.

Methods

First, clinical data of NSCLC presenting with BM were retrospectively reviewed. All of the patients had received total intracranial resection and were randomly distributed to developing cohort and validation cohort by 2:1. Second, we stratified the cohort using a recursive partitioning analysis(RPA), a score index for radiosurgery (SIR), a basic score for BM (BS-BM), a Golden Grading System (GGS), a disease-specific graded prognostic assessment (DS-GPA) and by NSCLC-RADES. The predictive power of the six PIs was assessed using the Kaplan–Meier method and the log-rank test. Third, univariate and multivariate analysis were explored, and the nomogram predicting survival of BMs from NSCLC was constructed using R 3.2.3 software. The concordance index (C-index) was calculated to evaluate the discriminatory power of the nomogram in the developing cohort and validation cohort.

Results

BS-BM could better predict survival of patients before intracranial surgery compared with other PIs. In the final multivariate analysis, KPS at diagnosis of BM, metachronous or synchronous BM and the histology of lung cancer appeared to be the independent prognostic predictors for survival. The C-index in the developing cohort and validation cohort were 0.75 and 0.71 respectively, which was better than the C-index of the other six PIs.

Conclusions

The new nomogram is a promising tool in further choosing the candidates for intracranial surgery among NSCLC with BM and in helping physicians tailor suitable treatment options before operation in clinical practice.
Literature
2.
go back to reference Hubbs JL, Boyd JA, Hollis D, Chino JP, Saynak M, Kelsey CR. Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer. 2010;116(21):5038–46. doi:10.1002/cncr.25254. CrossRefPubMed Hubbs JL, Boyd JA, Hollis D, Chino JP, Saynak M, Kelsey CR. Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer. 2010;116(21):5038–46. doi:10.​1002/​cncr.​25254.​ CrossRefPubMed
5.
go back to reference Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745–51.CrossRefPubMed Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745–51.CrossRefPubMed
6.
go back to reference Weltman E, Salvajoli JV, Brandt RA, de Morais Hanriot R, Prisco FE, Cruz JC, et al. Radiosurgery for brain metastases: a score index for predicting prognosis. Int J Radiat Oncol Biol Phys. 2000;46(5):1155–61.CrossRefPubMed Weltman E, Salvajoli JV, Brandt RA, de Morais Hanriot R, Prisco FE, Cruz JC, et al. Radiosurgery for brain metastases: a score index for predicting prognosis. Int J Radiat Oncol Biol Phys. 2000;46(5):1155–61.CrossRefPubMed
7.
8.
go back to reference Golden DW, Lamborn KR, McDermott MW, Kunwar S, Wara WM, Nakamura JL, et al. Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site. J Neurosurg. 2008;109(Suppl):77–86. doi:10.3171/jns/2008/109/12/s13.PubMed Golden DW, Lamborn KR, McDermott MW, Kunwar S, Wara WM, Nakamura JL, et al. Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site. J Neurosurg. 2008;109(Suppl):77–86. doi:10.​3171/​jns/​2008/​109/​12/​s13.PubMed
9.
go back to reference Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655–61. doi:10.1016/j.ijrobp.2009.08.025. CrossRefPubMed Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655–61. doi:10.​1016/​j.​ijrobp.​2009.​08.​025.​ CrossRefPubMed
10.
go back to reference Rades D, Dziggel L, Segedin B, Oblak I, Nagy V, Marita A, et al. A new survival score for patients with brain metastases from non-small cell lung cancer. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 2013;189(9):777–81. doi:10.1007/s00066-013-0362-x.CrossRef Rades D, Dziggel L, Segedin B, Oblak I, Nagy V, Marita A, et al. A new survival score for patients with brain metastases from non-small cell lung cancer. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 2013;189(9):777–81. doi:10.​1007/​s00066-013-0362-x.CrossRef
14.
go back to reference Muacevic A, Wowra B, Siefert A, Tonn JC, Steiger HJ, Kreth FW. Microsurgery plus whole brain irradiation versus gamma knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial. J Neuro-Oncol. 2008;87(3):299–307. doi:10.1007/s11060-007-9510-4. CrossRef Muacevic A, Wowra B, Siefert A, Tonn JC, Steiger HJ, Kreth FW. Microsurgery plus whole brain irradiation versus gamma knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial. J Neuro-Oncol. 2008;87(3):299–307. doi:10.​1007/​s11060-007-9510-4.​ CrossRef
18.
go back to reference Pessina F, Navarria P, Cozzi L, Ascolese AM, Maggi G, Rossi M, et al. The role of surgical resection in patients with single large brain metastases: feasibility, morbidity and local control evaluation. World neurosurgery. 2016. doi:10.1016/j.wneu.2016.06.098. Pessina F, Navarria P, Cozzi L, Ascolese AM, Maggi G, Rossi M, et al. The role of surgical resection in patients with single large brain metastases: feasibility, morbidity and local control evaluation. World neurosurgery. 2016. doi:10.​1016/​j.​wneu.​2016.​06.​098.​
19.
go back to reference Kaul D, Angelidis A, Budach V, Ghadjar P, Kufeld M, Badakhshi H. Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer. Radiation Oncology (London, England). 2015;10:244. doi:10.1186/s13014-015-0550-1. CrossRef Kaul D, Angelidis A, Budach V, Ghadjar P, Kufeld M, Badakhshi H. Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer. Radiation Oncology (London, England). 2015;10:244. doi:10.​1186/​s13014-015-0550-1.​ CrossRef
20.
go back to reference Agboola O, Benoit B, Cross P, Da Silva V, Esche B, Lesiuk H, et al. Prognostic factors derived from recursive partition analysis (RPA) of radiation therapy oncology group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases. Int J Radiat Oncol Biol Phys. 1998;42(1):155–9.CrossRefPubMed Agboola O, Benoit B, Cross P, Da Silva V, Esche B, Lesiuk H, et al. Prognostic factors derived from recursive partition analysis (RPA) of radiation therapy oncology group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases. Int J Radiat Oncol Biol Phys. 1998;42(1):155–9.CrossRefPubMed
21.
go back to reference Nieder C, Geinitz H, Molls M. Validation of the graded prognostic assessment index for surgically treated patients with brain metastases. Anticancer Res. 2008;28(5b):3015–7.PubMed Nieder C, Geinitz H, Molls M. Validation of the graded prognostic assessment index for surgically treated patients with brain metastases. Anticancer Res. 2008;28(5b):3015–7.PubMed
23.
go back to reference Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer. 1984;53(9):2002–7.CrossRefPubMed Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer. 1984;53(9):2002–7.CrossRefPubMed
25.
go back to reference Kuremsky JG, Urbanic JJ, Petty WJ, Lovato JF, Bourland JD, Tatter SB, et al. Tumor histology predicts patterns of failure and survival in patients with brain metastases from lung cancer treated with gamma knife radiosurgery. Neurosurgery 2013;73(4):641–647; discussion 7 doi:10.1227/neu.0000000000000072. Kuremsky JG, Urbanic JJ, Petty WJ, Lovato JF, Bourland JD, Tatter SB, et al. Tumor histology predicts patterns of failure and survival in patients with brain metastases from lung cancer treated with gamma knife radiosurgery. Neurosurgery 2013;73(4):641–647; discussion 7 doi:10.​1227/​neu.​0000000000000072​.
27.
go back to reference Hansen J, Becker A, Kluth LA, Rink M, Steuber T, Zacharias M, et al. Assessing the clinical benefit of a nomogram to predict specimen-confined disease at radical prostatectomy in patients with high-risk prostate cancer: an external validation. Urologic oncology 2015;33(9):384e1–384e8. doi:10.1016/jurolonc2015.02.017. Hansen J, Becker A, Kluth LA, Rink M, Steuber T, Zacharias M, et al. Assessing the clinical benefit of a nomogram to predict specimen-confined disease at radical prostatectomy in patients with high-risk prostate cancer: an external validation. Urologic oncology 2015;33(9):384e1–384e8. doi:10.​1016/​jurolonc2015.​02.​017.​
28.
go back to reference Bevilacqua JL, Kattan MW, Fey JV, Cody HS, 3rd, Borgen PI, Van Zee KJ. Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3670–3679 doi:10.1200/jco.2006.08.8013. Bevilacqua JL, Kattan MW, Fey JV, Cody HS, 3rd, Borgen PI, Van Zee KJ. Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3670–3679 doi:10.​1200/​jco.​2006.​08.​8013.​
29.
go back to reference Graesslin O, Abdulkarim BS, Coutant C, Huguet F, Gabos Z, Hsu L, et al. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncology : Official J American Soc Clin Oncology. 2010;28(12):2032–7. doi:10.1200/jco.2009.24.6314. CrossRef Graesslin O, Abdulkarim BS, Coutant C, Huguet F, Gabos Z, Hsu L, et al. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncology : Official J American Soc Clin Oncology. 2010;28(12):2032–7. doi:10.​1200/​jco.​2009.​24.​6314.​ CrossRef
Metadata
Title
Survival time following resection of intracranial metastases from NSCLC-development and validation of a novel nomogram
Authors
Xiaoyu Ji
Yingjie Zhuang
Xiangye Yin
Qiong Zhan
Xinli Zhou
Xiaohua Liang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3763-x

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine